DISCOUNT ZERTIFIKAT - ASTRAZENECA ADR | Market Closed - Bid/Ask 11:30:57 2024-06-26 EDT | After market 14:47:20 | |||
| 68.18 EUR | +0.19% |
|
68.26 | +0.11% |
| Current month | +2.79% | ||
| 1 month | +2.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 68.18 | +0.19% |
| 24-06-25 | 68.05 | +0.27% |
| 24-06-24 | 67.87 | -0.07% |
| 24-06-21 | 67.92 | +0.41% |
| 24-06-20 | 67.64 | +0.62% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 11:30 am
More quotesStatic data
| Product type | Discount-Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MG39PE |
| ISIN | DE000MG39PE5 |
| Date issued | 2024-04-30 |
| Maturity | 2024-09-20 (86 Days) |
| Parity | 1 : 1 |
| Emission price | 66.86 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 68.27 € |
|---|---|
| Lowest since issue | 65.48 € |
| Spread | 0.06 € |
| Spread % | 0.09% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
159
USD
Average target price
174.4
USD
Spread / Average Target
+9.66%
- Stock Market
- Certificates
- Certificat
